AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03728881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM
Study NCT03089307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries- ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
Study NCT01912625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT01912625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01912625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT01912625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01912625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01912625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01912625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01912625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03623919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FallSensing multiplayer games
Description: FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance.
Study NCT01023984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEM - Transanal Endoscopic Microsurgery
Description: TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
Study NCT01023984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD - Endoscopic Submucosal Dissection
Description: an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
Study NCT01171651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX-594 followed by sorafenib
Description: Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
Study NCT02500693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isolation of circulating tumor cells (CTC) from veinous blood
Description: Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
Study NCT00495157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment
Description: Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Study NCT03613922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physiotherapy
Description: Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
Study NCT03613922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
Study NCT02218580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Study NCT02218580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Study NCT02218580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT04235881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Description: Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
Study NCT02319629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03148691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study NCT03148691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study NCT02674204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
Study NCT02674204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
Study NCT01442844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micrografting
Description: Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
Study NCT04244539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser Device.
Description: Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
Study NCT03863912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disney movie
Description: Disney movie on portable DVD Player.
Study NCT03863912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Description: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Study NCT03863912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Description: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Study NCT00274833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
Study NCT00495157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomarker-based adjustment
Description: Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Study NCT00495157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-based adjustment
Description: Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Study NCT00274833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
Study NCT00274833 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
Study NCT04424563 — intervention group
Intervention type: DEVICE
Intervention: ventilators
Description: all patients in both groups will be ventilated if shocked and no recordable blood pressure
Study NCT04424563 — intervention group
Intervention type: DRUG
Intervention: aminocaproic acid
Description: 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
Study NCT04424563 — intervention group
Intervention type: DRUG
Intervention: Novo Seven
Description: 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received
Study NCT01851538 — intervention group
Intervention type: OTHER
Intervention: Observational study; no intervention.
Study NCT04434352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz Duolith Low-Intensity Shockwave Therapy
Description: A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.
Study NCT02820467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluorescence angiography
Description: Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
Study NCT03183544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit
Description: The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
Study NCT00709956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost (5 µg)
Description: Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study NCT00709956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iloprost (5 µg)
Description: Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study NCT00709956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study NCT00709956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study NCT01573910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin ophthalmic solution, 0.5%
Study NCT01573910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin ophthalmic solution, 0.3%
Study NCT03209219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2A
Description: 3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
Study NCT03209219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Pill
Description: 100mg， oral, bid
Study NCT00643630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application
Study NCT00643630 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tetrix
Description: Twice daily topical application
Study NCT04673097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Description: low viscosity resin that can flow through the pores in the enamel surface
Study NCT04673097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Icon® resin infiltration
Description: low viscosity resin that can flow through the pores in the enamel surface
Study NCT04673097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI paste plus
Description: s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
Study NCT03538769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: electronic alert and clinical decision support system
Description: Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
Study NCT00854646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
Study NCT01905475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Study NCT01905475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05064657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble blowing method
Description: The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process.
Study NCT05064657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bubble blowing method
Description: The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process.
Study NCT01270334 — intervention group
Intervention type: OTHER
Intervention: PH meassurment
Description: meassuring ph USING PROBE
Study NCT04416802 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy
Description: The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS.
Study NCT01275014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
Study NCT01275014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
Study NCT00611247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide
Study NCT00825604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary angioplasty (PCI)
Description: optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
Study NCT01199666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: text message appointment and immunization reminders
Study NCT01199666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message
Description: text message appointment and immunization reminders
Study NCT03567902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope intubation
Description: C-MAC videolaryngoscope intubation
Study NCT03567902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope intubation
Description: Direct laryngoscope intubation
Study NCT01722461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01722461 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Ulthera System delivering no ultrasound energy
Study NCT00620061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24
Description: 24 mcg capsules for oral administration
Study NCT01948830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: 0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
Study NCT01541293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Study NCT01541293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Study NCT04235881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App REM volver a casa
Description: The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks.
Study NCT03184480 — intervention group
Intervention type: DRUG
Intervention: Arnuity Ellipta
Description: The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
Study NCT02214264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-Kindness meditation training
Description: Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
Study NCT02214264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Awareness meditation training
Description: Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
Study NCT02214264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude
Description: Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
Study NCT02214264 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
Study NCT03347032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions
Study NCT03347032 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Serial inflations and deflations as detailed in the arm/group descriptions
Study NCT03649971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab SC will be administered every 4 weeks.
Study NCT03649971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC will be administered every 4 weeks.
Study NCT03331497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Description: About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.